Search company, investor...

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$60M | 7 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+120 points in the past 30 days

About Causaly

Causaly offers an operating system for biomedical and health data. It is an AI platform to help researchers accelerate the development and testing of drugs. The company was founded in 2018 and is based in London, United Kingdom.

Headquarters Location

10 - 16 Elm Street

London, England, WC1X 0BJ,

United Kingdom

+44 7538004312


ESPs containing Causaly

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Drug R&D Tech

The biomedical natural language processing (NLP) market uses advanced algorithms and linguistic models to extract and analyze information from vast amounts of biomedical text data such as scientific literature, electronic health records, and clinical trial reports. By leveraging biomedical NLP solutions, researchers, clinicians, and pharmaceutical companies can gain actionable insights, discover h…

Causaly named as Highflier among 5 other companies, including nference, Huma.AI, and Biorelate.

Causaly's Products & Differentiators




Research containing Causaly

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Causaly in 7 CB Insights research briefs, most recently on Feb 5, 2024.

Expert Collections containing Causaly

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Causaly is included in 5 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

11,617 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.


Generative AI

799 items

Companies working on generative AI applications and infrastructure.


Digital Health 50

50 items

Latest Causaly News

From Revolut roots to $15M funding: Ukrainian founder’s fintech startup streamlining SMB invoice payments

Sep 28, 2023

According to reports, the average small business owner in the UK spends approximately five hours per week on invoice payments, contributing to a staggering £1.5 trillion annual transaction volume in the UK alone. Apron, based in London and known for its innovative fintech platform that significantly reduces the invoice processing time for small businesses, recently secured $15 million in Series A funding. The funding round was spearheaded by Index Ventures, renowned for supporting startups like Causaly , Worldover , and Sylvera . Further, Bessemer Venture Partners and Visionaries Club also participated in this funding round. With this new capital injection, Apron plans to grow its existing team of 20 professionals, featuring talent from prominent companies such as Meta, Revolut, Square, and Yandex. Remarkably, this funding also arrives shortly after Apron’s recent unveilings in the fintech sphere – Apron Hub and Apron Snap accounts. Apron – How does it work? According to the company press release, the signup process for Apron is swift, taking just three minutes, after which users can effortlessly manage their invoices. Invoices smoothly transition from accounting software to Apron or can be forwarded via email. Notably, Apron facilitates the simultaneous payment of multiple suppliers across 150+ countries and in 30+ currencies, ensuring fair exchange rates with no concealed fees. The platform simplifies the approval process by presenting payments and authorisations side by side, streamlining the approval and modification procedures. Founded in 2021 by Revolut product leader Bogdan Uzbekov, a Ukrainian native, Apron operates on a distinctive approach that aims to transform the payment flow across a user network by placing user needs at the core of their product design. Their platform, instead of replacing existing accounting software, it seamlessly integrates into established workflows, connecting with prevalent business and accounting software. This integration drastically reduces time-consuming tasks from hours to mere minutes. “What providers forget is that the people behind businesses are, well, people – and they want the same quality they’re familiar with in their consumer apps,” said Bogdan Uzbekov, founder and CEO of Apron. “Apron puts itself in the position of all these users – accountants, business owners and suppliers – and instead of trying to solve business payments from just one perspective, we create a town square where they can all come together to move money as smoothly as possible. We want to flip payments from being a blocker to being a booster: something that can be done quickly, securely and even give you a sense of joy and satisfaction.” Jan Hammer, the Index partner who joined the Apron board, said: “The needs of SMBs have been ignored for too long. Bogdan’s team have realised that if you build an amazing product, it will spread organically and at speed among small businesses and accountants. Apron have not just built a technically exceptional back-end payments platform: combined with their unique focus on the product experience for end-users, they have the potential to redefine how people pay invoices everywhere.” Dani Reid and Agnes Potter, friends and founders of the neighbourhood cafe Potter & Reid in Spitalfields, London, were one of Apron’s first customers. “To a lot of small business owners, accounting is the last thing we’re thinking about,” they say. “We’re thinking about increasing sales to become profitable and striving for this every day. Apron saves time and money, which helps you focus on the bigger picture.”

Causaly Frequently Asked Questions (FAQ)

  • When was Causaly founded?

    Causaly was founded in 2018.

  • Where is Causaly's headquarters?

    Causaly's headquarters is located at London.

  • What is Causaly's latest funding round?

    Causaly's latest funding round is Series B - II.

  • How much did Causaly raise?

    Causaly raised a total of $90.72M.

  • Who are the investors of Causaly?

    Investors of Causaly include Pentech, Index Ventures, EBRD Venture Capital, Alex Gorsky, Marathon Ventures and 11 more.

  • Who are Causaly's competitors?

    Competitors of Causaly include Consensus and 8 more.

  • What products does Causaly offer?

    Causaly's products include AA.


Compare Causaly to Competitors

Innoplexus Logo

Innoplexus is a company that focuses on the use of artificial intelligence and data in the healthcare and pharmaceutical industries. The company offers a range of services, including drug discovery and development, using proprietary artificial intelligence and machine learning technologies to provide insights from global data. These insights are used to understand the complexity of diseases and develop effective treatment strategies. The company primarily serves the pharmaceutical and biotech industries. It was founded in 2015 and is based in Eschborn, Germany.

Quertle Logo

Quertle is a leader in Biomedical Big Data with a focus on artificial intelligence and analytics. The company's BioAI™ Platform powers a suite of products that analyze biomedical textual information to deliver relevant insights and predictive analytics. Quertle's technology has been recognized with several awards, including one from the US National Library of Medicine, and is at the forefront of transforming Big Data text searching into actionable discovery and analytics. It is based in Henderson, Nevada.

InveniAI Logo

InveniAI uses AI to provide context in healthcare and life sciences applications. EvolverAI is InveniAI's augmented intelligence platform that combines human intuition based on experience and expertise with the comprehensiveness and scale of artificial intelligence. EvolverAI combines Big Data technology with machine learning to present to human experts massive and complex data sets in a manner that allow humans to decipher patterns and enables the generation of hypotheses. EvolverAI combines the tenets of deductive, inductive and abductive research in this journey of discovery. PharmGPS is InveniAI's Big Data platform applied to understanding how drugs work and which of them are useful in satisfying unmet medical needs. PharmGPS has collated and crystallized the cumulative wisdom of pharmaceutical and drug development research to identify the drugs that are most likely to succeed in the regulatory process and satisfy patients' needs. It utilizes machine learning and big data approaches to predict future potential of drugs that are still in early stages of clinical development.

Biorelate Logo

Biorelate is a company that focuses on using artificial intelligence and natural language processing to curate biomedical data, operating within the biopharma industry. The company offers a range of products and services that provide scientists with tools and insights for drug discovery and development, including a platform that accelerates research intelligence. Biorelate primarily serves the pharmaceutical and biotech industries. It was founded in 2014 and is based in Manchester, England.

Aitia Logo

Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.

Insitro Logo

Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and high-throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development (R&D). Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.